V
Vittorio Gebbia
Researcher at University of Palermo
Publications - 263
Citations - 13134
Vittorio Gebbia is an academic researcher from University of Palermo. The author has contributed to research in topics: Cancer & Chemotherapy. The author has an hindex of 40, co-authored 248 publications receiving 11892 citations. Previous affiliations of Vittorio Gebbia include University of Naples Federico II.
Papers
More filters
Journal ArticleDOI
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial.
Rafael Rosell,Enric Carcereny,Radj Gervais,A. Vergnenegre,Bartomeu Massuti,Enriqueta Felip,Ramon Palmero,Ramon Garcia-Gomez,Cinta Pallares,Jose Miguel Sanchez,Rut Porta,Manuel Cobo,Pilar Garrido,Flavia Longo,Teresa Moran,A. Insa,Filippo de Marinis,Romain Corre,Isabel Bover,Alfonso Illiano,Eric Dansin,Javier de Castro,Michele Milella,Noemi Reguart,Giuseppe Altavilla,Ulpiano Jimenez,Mariano Provencio,Miguel Angel Moreno,J. Terrasa,Jose Muñoz-Langa,Javier Valdivia,Dolores Isla,Manuel Domine,Olivier Molinier,Julien Mazieres,Nathalie Baize,Rosario García-Campelo,Gilles Robinet,Delvys Rodriguez-Abreu,Guillermo Lopez-Vivanco,Vittorio Gebbia,Lioba Ferrera-Delgado,Pierre Bombaron,R. Bernabé,Alessandra Bearz,Angel Artal,Enrico Cortesi,Christian Rolfo,Maria Sanchez-Ronco,Ana Drozdowskyj,Cristina Queralt,Itziar de Aguirre,Jose Luis Ramirez,Jose Javier Sanchez,Miguel Angel Molina,Miquel Taron,Luis Paz-Ares +56 more
TL;DR: Erlotinib has been shown to improve progression-free survival compared with chemotherapy when given as first-line treatment for Asian patients with non-small-cell lung cancer (NSCLC) with activating EGFR mutations as discussed by the authors.
Journal ArticleDOI
Chemotherapy for elderly patients with advanced non-small-cell lung cancer: The multicenter Italian lung cancer in the elderly study (MILES) phase III randomized trial
Cesare Gridelli,Francesco Perrone,Ciro Gallo,S. Cigolari,Antonio Rossi,Francovito Piantedosi,Santi Barbera,F. Ferraù,E. Piazza,Francesco Rosetti,M. Clerici,Oscar Bertetto,Sergio Federico Robbiati,Luciano Frontini,Cosimo Sacco,Federico Castiglione,Adolfo Favaretto,Silvia Novello,Maria Rita Migliorino,Giampietro Gasparini,Domenico Galetta,Rosario Vincenzo Iaffaioli,Vittorio Gebbia +22 more
TL;DR: Although quality of life was similar across the three treatment arms, the combination treatment was more toxic than the two drugs given singly and not more effective than single-agent vinorelbine or gemcitabine in the treatment of elderly patients with advanced NSCLC.
Journal ArticleDOI
Phase III Randomized Trial of FOLFIRI Versus FOLFOX4 in the Treatment of Advanced Colorectal Cancer: A Multicenter Study of the Gruppo Oncologico Dell’Italia Meridionale
Giuseppe Colucci,Vittorio Gebbia,G. Paoletti,Francesco Giuliani,Michele Caruso,Nicola Gebbia,Giacomo Cartenì,Biagio Agostara,G. Pezzella,L. Manzione,Nicola Borsellino,A. Misino,Sante Romito,Ernesto Durini,Stefano Cordio,Marisa Di Seri,Massimo Lopez,Evaristo Maiello +17 more
TL;DR: There is no difference in ORR, TTP, and OS for patients treated with the FOLFIRI or FOLFOX4 regimen, and both therapies seemed effective as first-line treatment in these patients.
Journal ArticleDOI
Gemcitabine alone or with cisplatin for the treatment of patients with locally advanced and/or metastatic pancreatic carcinoma: a prospective, randomized phase III study of the Gruppo Oncologia dell'Italia Meridionale.
Giuseppe Colucci,Francesco Giuliani,Vittorio Gebbia,M. Biglietto,Piergiorgio Rabitti,Generoso Uomo,Silvio Cigolari,Antonio Testa,Evaristo Maiello,Massimo Lopez +9 more
TL;DR: A prospective, randomized Phase III trial was performed to determine whether, compared with gemcitabine (GEM) alone, the addition of cisplatin (CDDP) to GEM was able to improve the time to disease progression and the clinical benefit rate in patients with advanced pancreatic adenocarcinoma.
Journal ArticleDOI
Symptomatic Toxicities Experienced During Anticancer Treatment: Agreement Between Patient and Physician Reporting in Three Randomized Trials
Massimo Di Maio,Ciro Gallo,Natasha B. Leighl,Maria Carmela Piccirillo,Gennaro Daniele,Francesco Nuzzo,Cesare Gridelli,Vittorio Gebbia,Fortunato Ciardiello,Sabino De Placido,Anna Ceribelli,Adolfo Favaretto,Andrea de Matteis,Ronald Feld,Charles Butts,Jane Bryce,Simona Signoriello,Alessandro Morabito,Gaetano Rocco,Francesco Perrone +19 more
TL;DR: Subjective toxicities are at high risk of under-reporting by physicians, even when prospectively collected within randomized trials, and this strongly supports the incorporation of patient-reported outcomes into toxicity reporting in clinical trials.